Abstract
The gradual alignment with all of drug metabolism with all aspects of drug discovery and development has led to a complete realignment of the way the work is conducted. From a background of conducting bespoke in vivo studies much of the work is now in a high throughput screening mode. Large technological advances have been made, but the nature of drug metabolism processes, being multi-system and promiscuous means that much of the help provided to the medicinal chemistry is reactive rather than based on fundamental disposition structure-activity relationships. Lessons learned around the chemical and physicochemical properties more often associated with succesfull discovery and development projects are only moderately helpful when the high value pharmacological targets of today only yield potent ligands outside of the boundaries these properties describe. Pivotal to the impact of these properties is the intrinsic permeability of a molecule, something not as widely recognised as perhaps it should be. Metabolic lability is still a problem and the tactics employed are unchanged in 20 years: attempt to lower lipophilicity, if it is too high overall or introduce blocking groups, particularly halogens, after identifying the sites of metabolism Perhaps the greatest success drug metabolism science has had over the last fifteen years is its pivotal role in characterising drug-drug interactions and providing screening systems and computational models to investigate them. It still has many undeveloped areas of the science such as the role of metabolites in drug activity and why compounds vary in their extent of biliary excretion.
Keywords: Screening, CYP450, transporters, permeability, bile, metabolites, physicochemistry
Current Topics in Medicinal Chemistry
Title: Discovery and ADMET: Where Are We Now
Volume: 11 Issue: 4
Author(s): Dennis A. Smith
Affiliation:
Keywords: Screening, CYP450, transporters, permeability, bile, metabolites, physicochemistry
Abstract: The gradual alignment with all of drug metabolism with all aspects of drug discovery and development has led to a complete realignment of the way the work is conducted. From a background of conducting bespoke in vivo studies much of the work is now in a high throughput screening mode. Large technological advances have been made, but the nature of drug metabolism processes, being multi-system and promiscuous means that much of the help provided to the medicinal chemistry is reactive rather than based on fundamental disposition structure-activity relationships. Lessons learned around the chemical and physicochemical properties more often associated with succesfull discovery and development projects are only moderately helpful when the high value pharmacological targets of today only yield potent ligands outside of the boundaries these properties describe. Pivotal to the impact of these properties is the intrinsic permeability of a molecule, something not as widely recognised as perhaps it should be. Metabolic lability is still a problem and the tactics employed are unchanged in 20 years: attempt to lower lipophilicity, if it is too high overall or introduce blocking groups, particularly halogens, after identifying the sites of metabolism Perhaps the greatest success drug metabolism science has had over the last fifteen years is its pivotal role in characterising drug-drug interactions and providing screening systems and computational models to investigate them. It still has many undeveloped areas of the science such as the role of metabolites in drug activity and why compounds vary in their extent of biliary excretion.
Export Options
About this article
Cite this article as:
A. Smith Dennis, Discovery and ADMET: Where Are We Now, Current Topics in Medicinal Chemistry 2011; 11 (4) . https://dx.doi.org/10.2174/156802611794480909
DOI https://dx.doi.org/10.2174/156802611794480909 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Current Respiratory Medicine Reviews Roles of Renal Proximal Tubule Transport in the Pathogenesis of Hypertension
Current Hypertension Reviews Ethosomes as Novel Vesicular Carrier: An Overview of the Principle, Preparation and its Applications
Current Drug Delivery Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Pathogenesis of Diabetic Retinopathy and Diabetic Macular Edema and Enzyme Inhibition
Current Enzyme Inhibition Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Renal and Urological Diseases of the Newborn Neonatal Acute Kidney Injury
Current Pediatric Reviews A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews Animal Models for the Development of New Neuropharmacological Therapeutics in the Status Epilepticus
Current Neuropharmacology Synthesis and Biological Activity of Quaternary Quinolinium Salts: A Review
Current Organic Chemistry Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Recent Advances in the MCRs Synthesis of Chromenes: A Review
Current Organic Chemistry Calcium-Independent Membrane Damage by Venom Phospholipases A2
Protein & Peptide Letters Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke
Current Neuropharmacology